Global Blood Plasma Market Size By Component (Immunoglobulin, Albumin), By End-User (Hospitals, Clinics), By Geographic Scope And Forecast

Blood Plasma Market Size And Forecast

Blood Plasma Market size was valued at USD 41.26 Billion in 2024 and is projected to reach USD 83.44 Billion by 2032, growing at a CAGR of 9.2% from 2026 to 2032.

• Blood plasma is the yellowish, liquid component of blood that remains after the blood cells (red cells, white cells, and platelets) have been removed. Comprising about 55% of total blood volume, plasma is primarily composed of water (around 90%), along with proteins, electrolytes, hormones, nutrients, and waste products.
• It serves as a crucial medium for transporting these substances throughout the body, playing an essential role in maintaining blood pressure, pH balance, and overall homeostasis.
• Plasma has numerous medical applications, particularly in transfusion medicine and therapeutic treatments. It is vital for the production of clotting factor concentrates for patients with hemophilia and is also used in the formulation of immunoglobulins to treat various immune deficiencies.
• Additionally, plasma-derived products, such as albumin and clotting factors, are critical in managing conditions like liver disease, shock, and burns. In recent years, plasma has also gained attention for its potential in regenerative medicine, including applications in wound healing and aesthetic treatments.

Global Blood Plasma Market Dynamics

The key market dynamics that are shaping the global blood plasma market include:

Key Market Drivers

• Rising Demand for Plasma-Derived Therapies: The rising demand for plasma-derived therapies is significantly driving the blood plasma market. Conditions such as hemophilia and immune deficiencies require these therapies for effective treatment. According to the Plasma Protein Therapeutics Association (PPTA), the global market for plasma-derived therapies reached USD 28.6 Billion in 2023, with a projected CAGR of 6.8% through 2028.
• Growing Awareness of Blood Donation: Growing awareness of the importance of blood donation is increasing the availability of plasma. Public health campaigns are encouraging more individuals to donate, thereby expanding the plasma supply. According to the Plasma Protein Therapeutics Association (PPTA), the global market for plasma-derived therapies reached USD 28.6 Billion in 2023, with a projected CAGR of 6.8% through 2028.
• Increasing Incidence of Chronic Diseases: The increasing incidence of chronic diseases, such as autoimmune disorders, is boosting the need for plasma products. This trend emphasizes the essential role of plasma in managing complex health conditions. According to the Centers for Disease Control and Prevention (CDC), as of 2023, an estimated 6% of the U.S. population was living with an autoimmune disease, up from 4.5% in 2018.
• Rising Investment in Biotechnology: Rising investment in biotechnology and research is enhancing the development of plasma-derived products. Innovations in processing and formulation are leading to more effective therapies and expanded applications. The National Institutes of Health (NIH) reported that funding for research related to plasma-derived therapies reached USD 1.2 Billion in fiscal year 2023, a 15% increase from the previous year.
• Growing Regulatory Support for Plasma Products: Growing regulatory support for the safety and efficacy of plasma products is fostering market confidence. This supportive environment encourages manufacturers to invest in quality improvements and new product development. The FDA reported a 30% increase in the number of approved plasma-derived therapies in 2023 compared to 2020, reflecting a more streamlined approval process and growing confidence in these products.

Key Challenges:

• Increasing Regulatory Scrutiny: The increasing regulatory scrutiny surrounding blood plasma collection and use can hinder market expansion. Compliance with stringent guidelines adds complexity and costs for manufacturers and distributors.
• Rising Concerns over Donor Safety: Rising concerns about donor safety and the potential for adverse effects can affect plasma supply. These apprehensions may discourage individuals from donating, leading to shortages in plasma availability.
• Growing Public Perception Issues: Growing public perception issues related to blood donation and plasma products can create barriers to market growth. Misinformation or negative sentiments can deter potential donors and consumers alike.
• Growing Competition from Alternatives: Growing competition from alternative therapies and treatments poses a challenge to the blood plasma market. Emerging technologies may offer substitutes that reduce reliance on traditional plasma-derived therapies.

Key Trends

• Rising Focus on Immunoglobulin Therapies: The rising focus on immunoglobulin therapies is transforming the blood plasma market. As awareness grows about the effectiveness of these treatments for immune deficiencies and autoimmune diseases, demand is surging. Healthcare providers are increasingly prescribing immunoglobulin therapies, leading to greater investment in plasma collection and processing. This trend highlights the critical role of plasma-derived products in modern medicine.
• Growing Demand for Plasma-Derived Biologics: There is a growing demand for plasma-derived biologics, including clotting factors and albumin, essential for managing various medical conditions. This trend is fueled by an increasing prevalence of chronic diseases, surgical procedures, and trauma care needs. As more patients require these life-saving therapies, manufacturers are expanding their product lines to meet this demand. The emphasis on high-quality biologics is driving innovation in plasma processing technologies.
• Increasing Adoption of Automated Plasma Collection: The increasing adoption of automated plasma collection technologies is revolutionizing the industry. Automation improves the efficiency and safety of the collection process, resulting in higher yields and enhanced donor experience. As facilities implement these advanced systems, they can better meet the rising demand for plasma products. This trend not only streamlines operations but also helps attract more donors by minimizing discomfort during the collection process.

Global Blood Plasma Market Regional Analysis

Here is a more detailed regional analysis of the global blood plasma market:

North America

• North America leads the global blood plasma market, driven by advanced healthcare infrastructure, high awareness of plasma-derived therapies, and a well-established plasma collection network. The United States dominates the region's market share, with its robust regulatory framework and high plasma donation rates.
• According to the U.S. Food and Drug Administration, there were 943 licensed plasma collection centers in the country as of 2023, demonstrating the significant capacity for plasma collection and processing in the region.
• The region's dominance is further strengthened by the presence of major plasma fractionation companies and their ongoing investments in expanding production capabilities. Key players like CSL Limited and Grifols S.A. have been actively increasing their plasma collection and fractionation capacities to meet growing demand. In a recent development, Grifols announced in March 2024 the opening of a new plasma fractionation facility in North Carolina, USA, with an annual capacity of processing 6 million liters of plasma, potentially boosting the region's market position.

Asia Pacific

• The Asia Pacific region is experiencing rapid growth in the Blood Plasma Market, driven by improving healthcare infrastructure, increasing awareness of plasma-derived therapies, and rising prevalence of chronic diseases. Countries like China, India, and Japan are at the forefront of this expansion, with their governments investing heavily in healthcare systems and promoting plasma donation.
• According to China's National Medical Products Administration, the country's plasma-derived medicinal products market reached 30.8 billion yuan in 2023, highlighting the significant growth potential in the region.
• The market's growth is further propelled by the rising demand for immunoglobulins and other plasma-derived products for treating various immune deficiencies and rare diseases. Key players in the global blood plasma market are recognizing this potential and expanding their presence in Asia Pacific. In a recent development, Takeda Pharmaceutical Company Limited announced in February 2024 the completion of its new plasma fractionation facility in Guangzhou, China, with an annual production capacity of 1.2 million liters of plasma, aimed at meeting the growing demand for plasma-derived therapies in the region.

Global Blood Plasma Market: Segmentation Analysis

The Global Blood Plasma Market is segmented based on Component, End-User, And Geography.

Blood Plasma Market, By Component

• Immunoglobulin
• Albumin
• Coagulation Factor Concentrates
• Others

Based on Component, the Global Blood Plasma Market is bifurcated into Immunoglobulin, Albumin, Coagulation Factor Concentrates, and Others. In the blood plasma market, immunoglobulin is the dominant component, primarily due to its critical role in treating various immune deficiencies and autoimmune disorders. Conversely, the albumin segment is rapidly growing, driven by its increasing applications in critical care settings, including surgeries and liver diseases, as well as its use in drug formulation. The rising demand for albumin-based therapies and its versatility in various medical applications are key factors contributing to this segment's expansion.

Blood Plasma Market, By End-User

• Hospitals
• Clinics
• Research Laboratories

Based on End-User, the Global Blood Plasma Market is bifurcated into Hospitals, Clinics, and Research Laboratories. In the blood plasma market, hospitals currently dominate as the primary end-user, driven by the high demand for plasma-derived therapies and transfusions in critical care settings. Meanwhile, the research laboratories segment is experiencing rapid growth, fueled by increasing investments in research related to plasma-derived products and their applications in various medical fields. The expansion of biopharmaceutical research and the development of new therapies utilizing plasma components are key factors contributing to the growth of this segment.

Blood Plasma Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Blood Plasma Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the blood plasma market, North America is the dominant region, primarily due to its advanced healthcare infrastructure, high prevalence of plasma-derived therapies, and significant investment in research and development. Conversely, the Asia Pacific region is rapidly growing, driven by increasing healthcare expenditures, rising awareness of plasma therapies, and the expansion of healthcare facilities in countries like China and India. This growth is further supported by a rising incidence of chronic diseases and the demand for innovative treatment options, positioning Asia Pacific as a key area for future market expansion.

Key Players

The "Global Blood Plasma Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are CSL Behring, Grifols, Baxter International, Inc., Octapharma, Shire (now part of Takeda Pharmaceutical Company), Kedrion Biopharma, Bio Products Laboratory, China Biologic Products Holdings, Inc., LFB Group, Biotest AG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Blood Plasma Market Key Developments

• In September 2023, Grifols announced the expansion of its plasma collection network in North America, aiming to increase access to high-quality plasma for immunotherapy and other treatments.
• In August 2023, CSL Behring launched a new high-purity immunoglobulin product, enhancing treatment options for patients with immune deficiencies and autoimmune diseases.